Georgianna M Harris

US Patent:

6352997, Mar 5, 2002

Filed:

May 3, 1999

Appl. No.:

09/303852

Inventors:

Joanne Waldstreicher - Scotch Plains NJ
Georgianna S. Harris - Tinton Falls NJ

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

A61K 3147

US Classification:

514284, 544318, 544408, 546 77, 546 78, 546 14

Abstract:

The present invention provides for a method of treating polycystic ovary syndrome in a subject in need of such treatment comprising the administration of a therapeutically effective amount of a compound of structural formula I: to the subject. The present invention further provides for a method for improving fertility and the response to in vitro fertilization (I. V. F. ), comprising administration of therapeutically effective amount of compound of structural formula I to the subject. Further, the present invention provides for compositions useful in the methods of the present invention, as well as a method of manufacture of a medicament useful for treating polycystic ovary syndrome or for improving fertility or the response to in vitro fertilization (I. V. F. ).

US Patent:

6555358, Apr 29, 2003

Filed:

Mar 8, 2000

Appl. No.:

09/521511

Inventors:

Anne Gurnett - Dobbs Ferry NY
Paul A. Liberator - Holmdel NJ
Robert Donald - South Orange NJ
Dennis Schmatz - Cranford NJ
Georgianna Harris - Tinton Falls NJ
Sandra J. Rattray - Somerset NJ

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

C12N 110

US Classification:

4352584, 536 232, 435194, 4353201, 435419, 4352523, 43525411

Abstract:

Protozoal cyclic GMP dependent protein kinases have been isolated and cloned. These enzymes may be used in screening assays to identify potential antiprotozoal agents.

US Patent:

7125700, Oct 24, 2006

Filed:

Jan 21, 2003

Appl. No.:

10/348155

Inventors:

Anne Gurnett - New York NY, US
Robert Donald - South Orange NJ, US
Georgianna Harris - Tinton Falls NJ, US
Paul A. Liberator - Holmdel NJ, US
Dennis Schmatz - Cranford NJ, US
Sandra J. Rattray - Somerset NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C12N 9/12

US Classification:

435194

Abstract:

Protozoal cyclic GMP dependent protein kinases have been isolated and cloned. These enzymes may be used in screening assays to identify potential antiprotozoal agents.

US Patent:

7718390, May 18, 2010

Filed:

Sep 21, 2006

Appl. No.:

11/525062

Inventors:

Anne Gurnett - New York NY, US
Robert Donald - South Orange NJ, US
Georgianna Harris - Tinton Falls NJ, US
Paul A. Liberator - Holmdel NJ, US
Dennis Schmatz - Cranford NJ, US
Sandra J. Rattray - Somerset NJ, US

Assignee:

Merial Limited - Duluth GA

International Classification:

C12Q 1/48
C12N 9/12

US Classification:

435 15, 435194

Abstract:

Protozoal cyclic GMP dependent protein kinases have been isolated and cloned. These enzymes may be used in screening assays to identify potential antiprotozoal agents.

US Patent:

59359684, Aug 10, 1999

Filed:

Mar 12, 1998

Appl. No.:

9/041431

Inventors:

Joanne Waldstreicher - Scotch Plains NJ
Georgianna S. Harris - Tinton Falls NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3147
A61K 3158

US Classification:

514284

Abstract:

The present invention provides for a method of treating polycystic ovary syndrome in a subject in need of such treatment comprising the administration of a therapeutically effective amount of a compound of structural formula I: ##STR1## to the subject. The present invention further provides for a method for improving fertility and the response to in vitro fertilization (I. V. F. ), comprising administration of therapeutically effective amount of compound of structural formula I to the subject. Further, the present invention provides for compositions useful in the methods of the present invention, as well as a method of manufacture of a medicament useful for treating polycystic ovary syndrome or for improving fertility or the response to in vitro fertilization (I. V. F. ).

US Patent:

57564809, May 26, 1998

Filed:

Oct 24, 1996

Appl. No.:

8/738546

Inventors:

Herb G. Bull - Westfield NJ
Georgianna Harris - Tinton Falls NJ
Robert W. Myers - Cresskill NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07H 1904
C07H 19048
A61K 31705

US Classification:

514 47

Abstract:

The invention concerns the treatment of hyperandrogenic conditions in humans by the formation of a novel mechanism-based irreversible inhibitor of human 5. alpha. -reductase enzymes from 3-oxo-4-oxa end 4-thiasteroids having a 1,2-double bond and the pyridine-nucleotide cofactor of the 5. alpha. -reductase enzyme, NADPH. The invention further relates to the isolated inhibitor-cofactor complex.

US Patent:

59624426, Oct 5, 1999

Filed:

May 5, 1997

Appl. No.:

8/836341

Inventors:

Herb G. Bull - Westfield NJ
Georgianna S. Harris - Tinton Falls NJ

Assignee:

Merck & Co., INc. - Rahway NJ

International Classification:

A01N 4500

US Classification:

514169

Abstract:

The invention concerns the treatment of hyderandrogenic conditions in humans by the formation of a novel mechanism-based irreversible inhibitor of human 5. alpha. -reductase enzymes from 3-oxo-4-azasteroids having a 1,2-double bond and the pyridine-nucleotide cofactor of the 5. alpha. -reductase enzyme, NADPH. Until the present invention, it was not know or predicted that 3-oxo-4-azasteroids having 1,2-double bond would form a complex with NADPH by the mechanism of 5. alpha. -reductase in vivo. The invention further relates to the novel inhibitor-cofactor complex and pharmaceutical compositions containing the complex.

US Patent:

56566131, Aug 12, 1997

Filed:

Jan 4, 1995

Appl. No.:

8/368513

Inventors:

Herb G. Bull - Westfield NJ
Georgianna S. Harris - Tinton Falls NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3170

US Classification:

514 47

Abstract:

The invention concerns the treatment of hyperandrogenic conditions in humans by the formation of a novel mechanism-based irreversible inhibitor of human 5. alpha. -reductase enzymes from 3-oxo-4-azasteroids having a 1,2-double bond and the pyridine-nucleotide cofactor of the 5. alpha. -reductase enzyme, NADPH. Until the present invention, it was not known or predicted that 3-oxo-4-azasteroids having a 1,2-double bond would form a complex with NADPH by the mechanism of 5. alpha. -reductase in vivo. The invention further relates to the novel inhibitor-cofactor complex and pharmaceutical compositions containing the complex.